Liver function parameters in HIV/HCV co-infected patients treated with amprenavir and ritonavir and correlation with plasma levels

New Microbiologica

Volumn 30, Issue 3, 2007, Pages 279-282

  Spagnuolo, Vincenzo ^a,b   Gentilini, Gianluca ^a   De Bona, Anna ^a   Galli, Laura ^a   Uberti Foppa, Caterina ^a   Soldarini, Armando ^a   Dorigatti, Fernanda ^a   Seminari, Elena ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b Institut of Infectious Diseases   (Italy)

Author keywords

Cirrhosis; Fos amprenavir; HCV infection

Indexed keywords

AMPRENAVIR; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE; PROTEINASE INHIBITOR; RITONAVIR; SULFONAMIDE;

ADULT; ARTICLE; COMPARATIVE STUDY; GENETICS; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; LIVER CIRRHOSIS; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; CARBAMATES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HEPACIVIRUS; HEPATITIS B VIRUS; HEPATITIS C, CHRONIC; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LIVER CIRRHOSIS; MIDDLE AGED; RITONAVIR; SULFONAMIDES; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

EID: 34547928887     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. ARANZABAL, L., CASADO, J.L., MOYA, J., QUEREDA, C., DIZ, S., MORENO, A., MORENO, L., ANTELA, A., PEREZ-ELIAS, M.J., DRONDA, F., MARIN, A., HERNANDEZ-RANZ, F., MORENO, A., MORENO, S. (2005). Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 15, 40 (4): 588-593.
2. BECQUEMONT, L., CHAZOUILLERES, O., ET AL. (2002). Effect of interferon α-ribavirin biotherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic active hepatitis C Clin Pharm Ther 71 (6), 488-495.
3. CANTA, F., MARRONE, R. ET AL. (2005). Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients. JAC 55 (2): 280-281.
4. COOPER, C.L., PARBHAKAR, M.A., ANGEL, J.B. (2002). Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individual coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 34, 1259-1263.
5. MAIDA, I., NUNEZ, M., ET AL. (2006) Severe liver disease associated with prolonged exposure to antiretroviral drugs. JAIDS 42 (2): 177-182.
6. MACÍAS, J., MIRA, J.A., ET AL. (2006). Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C Antivir Ther 11 (7): 839-846.
7. MERCHANTE, N., GIRÓN-GONZÁLEZ, J.A., ET AL. (2006). Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS 2, 20 (1): 49-57.
8. MOCROFT, A., SORIANO, V. ET AL. (2005). Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS 2, 19 (18): 2117-2125.
9. MOLTÓ, J., VALLE, M., ET AL. (2007). Lopinavir/ritonavir pharmacokinetics in HIV and hepatitis C virus co-infected patients without liver function impairment: influence of liver fibrosis. Clin Pharmacokinet 46 (1), 85-92.
10. MOULY, S., RIZZO-PADOIN, N. ET AL. (2006) Effect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients. Br J Clin Pharmacol 62, 2, 200-209.
11. SULKOWSKI, M.S., MEHTA, S.H. ET AL. (2004). Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS 18, 2277-2284.
12. SULKOWSKI, M.S., THOMAS, D.L., ET AL. (2000). Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitits C or B virus infection. JAMA 283, 74-80.
13. VERONESE, L., RAUTAUREAU, J., ET AL. (2000). Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function. Antimicrob Agents Chemother 44 (4), 821-826.